Skip to main content
. Author manuscript; available in PMC: 2024 Feb 16.
Published in final edited form as: Clin Imaging. 2020 Oct 13;70:18–24. doi: 10.1016/j.clinimag.2020.10.021

Table 3.

MR detected additional malignancy based on modality, mammographic breast density and MR breast parenchymal enhancement.

Discordant results (%) True positive (%) False positive (%) No additional disease (%)
DM cohort (n = 201) 48 (23%) 28 (14%) 18 (9%) 155 (77%)
DBT cohort (n = 187) 37 (20%)
p = 0.330
22 (12%)
p = 0.530
13 (7%)
p = 0.470
152 (81%)
p = 0.313
Non-dense (n = 195) 31 (16%) 19 (10%) 11(6%) 165 (85%)
Dense (n = 193) 54 (28%)
p = 0.004
31 (16%)
p = 0.062
20 (10%)
p = 0.086
142 (73%)
p = 0.007
Low BPE (n = 275) 52 (19%) 32 (12%) 17 (6%) 226 (88%)
High BPE (n = 113) 33 (30%)
p = 0.020
18 (16%)
p = 0.250
14 (13%)
p = 0.040
81 (72%)
p = 0.020

DM: digital mammography.

DBT: digital breast tomosynthesis.

BPE: background parenchymal enhancement.

No additional disease: defined as a negative result by MR.

The p-values of less than 0.05 are marked as bold.